Trials / Completed
CompletedNCT06809374
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Kochi University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gemcitabine | neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2025-02-05
- Last updated
- 2025-02-05
Source: ClinicalTrials.gov record NCT06809374. Inclusion in this directory is not an endorsement.